Company intelligence / Profile preview

Hopkins Capital Group II

Greenwich, Connecticut, United States

Ownership: Private
Development stage: Other

Overview

Hopkins Capital Group is a healthcare-focused venture capital and merchant banking firm that specializes in founding and financing transformative life science companies. Led by Kevin Kimberlin, the firm is well-known for its role as a founding investor in several landmark biotechnology companies, including Celgene, Myriad Genetics, and Osiris Therapeutics. The group focuses on identifying breakthrough medical technologies, such as DNA sequencing and stem cell therapy, and providing the strategic and financial support necessary to bring them to market. Hopkins Capital Group II serves as a specific investment vehicle within the broader group's portfolio management and venture activities.

Industry: Investors

Beyond the preview

Go deeper on Hopkins Capital Group II.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hopkins Capital Group II.

Explore the full profile